KRISTEN WILLIAMS, the Chief Administrative Officer of $PCRX, sold 10,259 shares of the company on 06-04-2026 for an estimated $228,467. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.8% of their shares of this class of stock. Following this trade, they now own 167,062 shares of this class of $PCRX stock.
$PCRX Insider Trading Activity
$PCRX insiders have traded $PCRX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- SHAWN CROSS (Chief Financial Officer) has made 0 purchases and 6 sales selling 50,000 shares for an estimated $1,254,945.
- KRISTEN WILLIAMS (Chief Administrative Officer) has made 0 purchases and 2 sales selling 23,396 shares for an estimated $498,170.
- LAUREN RIKER (Senior Vice President, Finance) has made 0 purchases and 2 sales selling 5,416 shares for an estimated $117,563.
- JONATHAN SLONIN (Chief Medical Officer) sold 3,261 shares for an estimated $74,416
- MARK FROIMSON sold 500 shares for an estimated $10,905
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PCRX Hedge Fund Activity
We have seen 119 institutional investors add shares of $PCRX stock to their portfolio, and 146 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 839,561 shares (-88.8%) from their portfolio in Q1 2026, for an estimated $18,974,078
- AMERICAN CENTURY COMPANIES INC removed 498,484 shares (-37.3%) from their portfolio in Q1 2026, for an estimated $11,265,738
- ASSENAGON ASSET MANAGEMENT S.A. removed 435,143 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9,834,231
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 409,997 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9,265,932
- VANGUARD GROUP INC removed 384,612 shares (-7.4%) from their portfolio in Q4 2025, for an estimated $9,953,758
- J. GOLDMAN & CO LP removed 339,481 shares (-77.6%) from their portfolio in Q1 2026, for an estimated $7,672,270
- BLACKROCK, INC. removed 328,937 shares (-4.7%) from their portfolio in Q1 2026, for an estimated $7,433,976
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PCRX Revenue
$PCRX had revenues of $177.4M in Q1 2026. This is an increase of 5.0% from the same period in the prior year.
You can track PCRX financials on Quiver Quantitative's PCRX stock page.
You can access data on PCRX stock through the Quiver Quantitative API.
$PCRX Analyst Ratings
Wall Street analysts have issued reports on $PCRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/01/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
To track analyst ratings and price targets for $PCRX, check out Quiver Quantitative's $PCRX forecast page.
$PCRX Price Targets
Multiple analysts have issued price targets for $PCRX recently. We have seen 4 analysts offer price targets for $PCRX in the last 6 months, with a median target of $28.5.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $32.0 on 05/01/2026
- Douglas Miehm from RBC Capital set a target price of $24.0 on 05/01/2026
- Glen Santangelo from Barclays set a target price of $25.0 on 03/26/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $38.0 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
